Cubist Pharmaceuticals - antibiotic and antimicrobial therapies for MRSA and other super bugs such as Clostridium-difficile and multi-drug resistant Gram-negative pathogens and other novel therapies for use in hospital and other acute care settings

Listen to Cubist President and CEO Michael W. Bonney's remarks on Innovation (16:32)

1Q10 Results

Replay of Cubist's April 15, 2010 earnings call that reported on Cubist's 1Q10 results and discussed 2010 guidance and expected milestones
Transcript of the April 15, 2010 earnings call
Presentation slides that accompanied the April 15, 2010 earnings call

4Q & FY09 Results

Replay of Cubists January 21, 2010 earnings call that reported on Cubists 4Q/FY09 results and discussed 2010 guidance and expected milestones
Transcript of the January 21, 2010 earnings call
Presentation slides that accompanied the January 21, 2010 earnings call

Click here for 4Q/FY09 webcast replay information
Click here for 4Q/FY09 transcript
Click here for the 4Q/FY09 presentation

Cubist Pharmaceuticals Named One of Fortune's "100 Fastest-Growing Companies"

Posted August 20, 2010

LEXINGTON, Mass.--(BUSINESS WIRE)-- Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced it has been ranked 31st on FORTUNE's 2010 "100 Fastest-Growing Companies" list and the top pharmaceutical company. In the "Profit Growth" subgroup Cubist ranked 21st. The magazine will be on the newsstands on August 23 and the full list is available today online.